Hypera S.A. (BVMF:HYPE3)

Brazil flag Brazil · Delayed Price · Currency is BRL
23.65
+0.29 (1.24%)
At close: Feb 6, 2026
24.67%
Market Cap14.97B +28.3%
Revenue (ttm)6.97B -10.4%
Net Income823.94M -47.5%
EPS1.29 -47.5%
Shares Out632.94M
PE Ratio18.26
Forward PE8.33
Dividend1.17 (4.95%)
Ex-Dividend DateDec 29, 2025
Volume3,020,300
Average Volume3,086,545
Open23.21
Previous Close23.36
Day's Range23.21 - 24.04
52-Week Range18.32 - 28.87
Beta0.24
RSI44.54
Earnings DateMar 12, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]

Sector Healthcare
Founded 1999
Employees 10,481
Stock Exchange Brazil Stock Exchange
Ticker Symbol HYPE3
Full Company Profile

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.

Financial Statements